Chronic Rhinosinusitis Phenotype With Nasal Polyps (CRSwNP)
3
Pipeline Programs
2
Companies
2
Clinical Trials
1 recruiting
0
Approved Products
Pipeline by Development Stage
Preclinical
Phase 1
Phase 1/2
Phase 2
Phase 2/3
Phase 3
On Market
0
0
0
0
0
3
0
Early DiscoveryClinical DevelopmentMarket
Competitive Landscape
2 companies ranked by most advanced pipeline stage
SanofiPARIS, France
2 programs1
Dupilumab SAR231893Phase 31 trial
Dupilumab - Standard DoseN/A1 trial
Active Trials
Trial Timeline
Clinical trial activity over time
2021
2022
2023
2024
2025
2026
2027
SanofiDupilumab SAR231893
SanofiDupilumab - Standard Dose
Clinical Trials (2)
Total enrollment: 478 patients across 2 trials
Controlled Clinical Study of Dupilumab in Patients With Nasal Polyps
Start: Nov 2016Est. completion: Nov 2018448 patients
Phase 3Completed
Olfactory Cleft Obstruction and Electrophysiological Field Potentials Predict Olfactory Restoration by Dupilumab in CRSwNP Patients.
Start: May 2025Est. completion: Dec 202730 patients
N/ARecruiting
Phase Legend
Preclinical— Lab & animal studies
Phase 1— Safety & dosing
Phase 2— Efficacy testing
Phase 3— Large-scale trials
On Market— Approved & available
Key Insights
3 late-stage (Phase 3) programs — potential near-term approvals
1 actively recruiting trials targeting 478 patients
2 companies competing in this space